文献速递糖尿病

达格列净辅助胰岛素治疗1型糖尿病52周:DEPICT试验事后肾脏分析

Effect of dapagliflozin as an adjunct to insulin over 52 weeks in individuals with type 1 diabetes: post-hoc renal analysis of the DEPICT randomised controlled trials.
PubMed 文献 · Lancet Diabetes Endocrinol · 2020-01-01

基于DEPICT-1和DEPICT-2两项随机对照试验的汇总数据,事后分析251例基线存在白蛋白尿的1型糖尿病患者。结果显示,与安慰剂相比,达格列净10mg治疗52周可显著降低尿白蛋白肌酐比值(UACR),而eGFR无显著变化,安全性与已知一致。

要点

  • 达格列净10mg辅助胰岛素可降低1型糖尿病伴白蛋白尿患者的UACR。
  • 达格列净5mg和10mg对eGFR均无显著影响。
  • 安全性与安慰剂组相似,未发现新的安全信号。

核心结论

  • 达格列净辅助胰岛素治疗可降低1型糖尿病伴白蛋白尿患者的UACR,可能具有肾脏保护获益。

研究设计与样本

  • DEPICT-1和DEPICT-2随机对照试验的事后汇总分析,纳入251例基线UACR≥30 mg/g的1型糖尿病患者。

主要发现

  • 各组不良事件和严重不良事件比例相似,包括低血糖和糖尿病酮症酸中毒。

临床怎么用

  • 对于1型糖尿病合并白蛋白尿且胰岛素控制不佳的患者,可考虑达格列净10mg辅助治疗以降低UACR,但需监测低血糖和酮症酸中毒风险。

局限性

  • 事后分析,非预设终点,需前瞻性研究确认肾脏保护获益。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: The DEPICT-1 and DEPICT-2 studies showed that dapagliflozin as an adjunct to insulin in individuals with inadequately controlled type 1 diabetes improved glycaemic control and bodyweight, without increase in risk of hypoglycaemia. We aimed to determine the effect of dapagliflozin on urinary albumin-to-creatinine ratio (UACR) and estimated glomerular filtration rate (eGFR) using pooled data from the DEPICT studies. METHODS: In this post-hoc analysis, we used data pooled from both DEPICT studies (DEPICT-1 ran from Nov 11, 2014, to Aug 25, 2017; DEPICT-2 ran from July 8, 2015, to April 18, 2018), in which participants were aged 18-75 years, with inadequately controlled type 1 diabetes and with a baseline UACR of at least 30 mg/g. In the DEPICT studies, participants were randomly assigned (1:1:1) to receive dapagliflozin (5 mg or 10 mg) or placebo all plus insulin, for 24 weeks, with a 28-week long-term extension (ie, 52 weeks in total). In this post-hoc analysis, we assessed the percentage change from baseline in UACR and in eGFR, up to 52 weeks. UACR, eGFR, and safety were assessed in all eligible participants who had received at least one dose of study drug. HbA1c, bodyweight, and systolic blood pressure were assessed in all participants who received at least one dose of study drug during the first 24-week period, and who had a baseline and any post-baseline assessment for that parameter. The DEPICT trials were registered with ClinicalTrials.gov, NCT02268214 (DEPICT-1), NCT02460978 (DEPICT-2), and are now complete. RESULTS: 251 participants with albuminuria at baseline were included in this post-hoc analysis; of whom 80 (32%) had been randomly assigned to dapagliflozin 5 mg, 84 (33%) to dapagliflozin 10 mg, and 87 (35%) to placebo. Compared with placebo, treatment with both dapagliflozin doses improved UACR over 52 weeks. At week 52, mean difference in change from baseline versus placebo in UACR was -13·3% (95% CI -37·2 to 19·8) for dapagliflozin 5 mg and -31·1% (-49·9 to -5·2) for dapagliflozin 10 mg. No notable change from baseline was seen in eGFR, with a mean difference in change from baseline versus placebo of 3·27 mL/min per 1·73 m2 (95% CI -0·92 to 7·45) for dapagliflozin 5 mg and 2·12 mL/min per 1·73 m2 (-2·03 to 6·27) for dapagliflozin 10 mg. Similar proportions of participants in each treatment group had adverse events and serious adverse events, including hypoglycaemia and diabetic ketoacidosis; no new safety signals were identified in this population. INTERPRETATION: Treatment with dapagliflozin resulted in UACR reduction, which might provide renoprotective benefits in individuals with type 1 diabetes and albuminuria. Dedicated prospective studies are needed to confirm these findings as prespecified endpoints. FUNDING: AstraZeneca.

来源:Lancet Diabetes Endocrinol,查看原文。版权归原作者所有。

引用

  1. Groop PH, Dandona P, Phillip M, et al. Effect of dapagliflozin as an adjunct to insulin over 52 weeks in individuals with type 1 diabetes: post-hoc renal analysis of the DEPICT randomised controlled trials. Lancet Diabetes Endocrinol. 2020. PMID: 32946821. doi:10.1016/S2213-8587(20)30280-1

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。